How to Qualify for Inspire Sleep Apnea Treatment

Qualifying for Inspire therapy requires meeting several specific medical criteria, and the process involves more than just a single doctor visit. You need a diagnosis of moderate-to-severe obstructive sleep apnea, a documented inability to use CPAP, a body mass index below a certain threshold, and a favorable airway anatomy confirmed by a specialized procedure called drug-induced sleep endoscopy. Each of these checkpoints serves a purpose, and understanding them ahead of time can save you months of confusion.

The Core Eligibility Criteria

Inspire’s hypoglossal nerve stimulator was approved by the FDA in 2014 for adults with moderate-to-severe obstructive sleep apnea who cannot tolerate CPAP. The formal eligibility criteria have shifted slightly since the original clinical trial, but the current requirements include an apnea-hypopnea index (AHI) between 15 and 65 events per hour, a central apnea index making up less than 25% of total AHI, a BMI under 32, and no complete concentric collapse of the soft palate on sleep endoscopy.¹ You also need to be at least 18 years old, though a separate pathway exists for certain adolescents with Down syndrome.

The AHI is simply a count of how many times per hour your breathing partially or fully stops during sleep. An AHI of 15 to 30 is considered moderate sleep apnea; above 30 is severe. The original STAR clinical trial that led to FDA approval enrolled patients with an AHI between 20 and 50, but the approved range has since expanded to 15 through 65.² If your sleep study shows an AHI below 15, you have mild sleep apnea, and Inspire is not indicated. If your AHI is above 65, you fall outside the approved window as well.

One detail that trips people up is the central apnea index. Obstructive apneas happen when your airway physically collapses. Central apneas happen when your brain temporarily stops sending the signal to breathe. Inspire works by stimulating the nerve that controls your tongue, so it only helps with the obstructive type. If more than a quarter of your breathing events are central rather than obstructive, the device is unlikely to address enough of your problem to be worthwhile.

Why CPAP Failure Comes First

Inspire is not a first-line treatment. You must have tried CPAP and either failed to stick with it or been genuinely unable to tolerate it. The standard definition of CPAP non-adherence used in Inspire’s prescribing framework is using the machine fewer than four hours per night on at least 70% of nights.³ In practice, this means your CPAP usage data, which the machine records automatically, needs to show that you gave it a real try and it did not work.

Intolerance can mean many things. Some people experience claustrophobia from the mask. Others have chronic nasal congestion, skin irritation, or aerophagia (swallowing air) that makes CPAP miserable. Some find the pressure itself unbearable. Your sleep physician will typically ask whether you tried different mask styles, adjusted pressure settings, or used a heated humidifier before concluding that CPAP has failed. Insurance companies in particular want documentation showing you made a good-faith effort. Simply saying “I don’t like it” without any recorded usage data usually is not enough.

The Weight Requirement and Its Gray Area

The official guideline recommends a BMI below 32 for Inspire candidacy.⁴ For reference, a BMI of 32 corresponds to roughly 222 pounds for someone who is 5’10”, or about 192 pounds at 5’6″. This cutoff exists because excess weight, particularly around the neck and upper airway, can reduce how effectively the device opens the airway. Heavier patients also tend to have higher rates of the specific type of airway collapse that disqualifies candidates on endoscopy.⁵

That said, the BMI cutoff is more of a guideline than an absolute wall. Some Inspire centers and insurance plans now work with patients whose BMI falls between 32 and 35. Research from the ADHERE registry, a large multi-center tracking database, found that patients with a BMI between 32 and 35 had somewhat lower surgical success rates compared to those under 32 (about 60% versus 72%), but many still benefited meaningfully.⁶ A separate multi-institutional review found no significant difference in outcomes between patients above and below a BMI of 32 on several measures, including post-treatment AHI and daytime sleepiness.⁷ Some source materials reference a BMI limit of 35 rather than 32, reflecting this expanded real-world practice.³

If your BMI is above 35, most programs will ask you to lose weight before proceeding. This is not just a bureaucratic hurdle. Higher BMI is associated with worse outcomes, and insurance coverage becomes much harder to obtain beyond that range. If you are close to the cutoff, losing even a modest amount of weight can make you eligible and may independently improve your sleep apnea.

Drug-Induced Sleep Endoscopy

This is the step that surprises most patients. Before you can be approved for Inspire, you need a procedure called drug-induced sleep endoscopy, or DISE. During DISE, you are sedated in an operating room to simulate natural sleep while a thin flexible camera is passed through your nose to observe how and where your airway collapses.⁸

The specific thing your surgeon is looking for is called complete concentric collapse at the level of the soft palate. Imagine looking down a tube: if the walls collapse inward from all directions simultaneously, forming a perfect ring of closure, that is concentric collapse. Inspire works by pushing the tongue forward to open the airway, but it cannot counteract a palate that closes like a drawstring from every direction. Patients without this collapse pattern had dramatically better outcomes in the pivotal study, with their AHI dropping from an average of about 38 events per hour down to roughly 11.⁹

If DISE reveals complete concentric collapse, you are not a candidate for Inspire under current criteria. There is no workaround for this one. The collapse pattern is not something you can change through weight loss or therapy, though in some cases a prior palatal surgery may alter the anatomy enough to change the DISE result on a future exam. Your surgeon may discuss alternative surgical options if this is what disqualifies you.

What the Qualification Timeline Looks Like

Putting all the pieces together, the typical pathway from initial interest to device implantation involves several appointments spread over weeks or months. It usually goes something like this:

Sleep study: A polysomnogram (either in a lab or sometimes at home) confirms your AHI is in the 15 to 65 range and that your central apnea index is below 25% of total events.
CPAP trial: If you have not already tried CPAP, you will need to. Most insurance plans require documented evidence of CPAP failure over at least a few weeks to months.
ENT or sleep surgery consultation: A surgeon experienced with Inspire reviews your records, checks your BMI, and discusses whether you are a plausible candidate.
DISE: The endoscopy procedure, which typically takes about 15 to 20 minutes, determines whether your collapse pattern is compatible with the device.
Insurance authorization: Your surgeon’s office submits all the documentation. Insurance approval can take anywhere from a couple of weeks to over a month, depending on the payer.

Some patients complete this process in two to three months; others take six months or longer, especially if weight loss is needed or if insurance requires additional documentation.

What Happens During and After Surgery

The implantation itself is an outpatient surgery performed under general anesthesia, usually lasting about two hours. The procedure involves placing a stimulation electrode on the hypoglossal nerve (the nerve that controls the tongue) through an incision under the chin, a pulse generator in the upper chest similar to a pacemaker, and a breathing sensor between two ribs.¹⁰ Intraoperative testing confirms that the tongue responds properly to stimulation before the incisions are closed.

The device is not turned on immediately. You typically wait about a month for healing before activation, at which point the voltage and timing settings are adjusted during a sleep study or clinic visit. Fine-tuning continues over subsequent visits. The device is controlled by a small handheld remote: you turn it on at bedtime, and it delivers mild electrical pulses synchronized with your breathing to keep your airway open.¹¹

How Well It Works

For patients who meet the eligibility criteria, outcomes are encouraging. A systematic review and meta-analysis found that Inspire reduced the AHI by about 20 events per hour in the short term and about 16 events per hour over the long term.¹² At one year, the surgical success rate (defined as at least a 50% reduction in AHI plus an AHI below 20) was about 72%, and that rate held steady at the five-year mark around 75%.¹³

Beyond the sleep-study numbers, patients report less daytime sleepiness, better quality of life, and dramatically less snoring. In one follow-up study at 48 months, 85% of bed partners reported soft to no snoring.¹⁴ These improvements were consistent across multiple studies in different countries.¹⁵

Long-Term Device Maintenance

The pulse generator has a battery that eventually needs replacement, just like a pacemaker. In the first cohort of patients followed long enough to require it, battery replacement surgery happened an average of about 8 years after the initial implant.¹⁶ The replacement procedure is much quicker and simpler than the original implant, taking roughly an hour versus two and a half hours on average. Occasionally, the stimulation lead also needs replacing, which adds complexity, but this was uncommon.

MRI compatibility used to be a significant concern. Older Inspire models were limited to 1.5 Tesla scanners under restricted conditions, which could complicate future medical imaging. The newer Inspire IV and V systems have received FDA clearance for 3.0 Tesla MRI scans, which are the high-resolution scans used for detailed brain, joint, and cardiac imaging.¹⁷ If you are considering the device long-term, asking which model will be implanted is worth the conversation.

Cost and Insurance Coverage

Inspire surgery typically costs in the range of $30,000 to $50,000 or more when you factor in the device, surgical fees, and facility costs. Most major insurance plans, including Medicare, now cover it for patients who meet the eligibility criteria, but the approval process can be demanding. You will need documented sleep study results, evidence of CPAP failure, DISE findings, and sometimes a letter of medical necessity from your sleep physician.

From a health-economics perspective, modeling based on the STAR trial data projected that Inspire adds roughly one additional quality-adjusted life year over a patient’s lifetime compared to no treatment, at an estimated cost of about $39,500 per quality-adjusted life year gained. That figure falls well within the range that the U.S. healthcare system considers cost-effective.¹⁸ A similar analysis from a UK perspective also found the therapy cost-effective against the National Health Service’s willingness-to-pay thresholds.¹⁹ These findings matter because they are what convince insurance companies and national health systems to cover the procedure.

If You Do Not Qualify

Not meeting Inspire’s criteria does not mean you are out of options. Obstructive sleep apnea varies from person to person, and effective treatment often involves combining more than one approach.²⁰ Alternatives include:

Oral appliances: Custom-fitted mandibular advancement devices push the lower jaw forward during sleep to keep the airway open. They work best for mild-to-moderate sleep apnea.
Positional therapy: If your apnea is significantly worse on your back, devices or techniques that keep you sleeping on your side can help.
Traditional upper airway surgery: Procedures like uvulopalatopharyngoplasty (UPPP), genioglossus advancement, or maxillomandibular advancement physically restructure the airway.
Weight loss: Even a 10% reduction in body weight can substantially improve AHI in many patients, sometimes enough to drop from severe to mild.
Combination therapy: Using an oral appliance together with positional therapy, or pairing modest weight loss with a lower CPAP pressure, can be effective when single approaches fall short.

If your disqualifying factor is BMI, losing weight may eventually make you eligible. If it is complete concentric collapse on DISE, discussing palatal surgery or other structural procedures with a sleep surgeon is a reasonable next step. And if your AHI is too low for Inspire, the silver lining is that your sleep apnea is mild enough that less invasive treatments are likely to work.

Inspire for Adolescents With Down Syndrome

One population that falls outside the standard adult criteria but has its own pathway is adolescents with Down syndrome, who experience obstructive sleep apnea at very high rates and often do not tolerate CPAP at all. The FDA granted a humanitarian device exemption for Inspire in this group. In a study of 42 adolescents (average age about 15), Inspire reduced AHI by an average of roughly 13 events per hour, and about two-thirds of participants met the threshold for treatment response at 12 months. The most common side effect was temporary tongue discomfort, affecting about 12% of patients.²¹

Smaller, earlier studies in this population showed even more dramatic individual results, with some children achieving AHI reductions of 56% to 85% and device usage averaging over five hours per night.²² Long-term follow-up in a small group showed that these improvements persisted, with all tracked patients maintaining at least a 50% AHI reduction over extended observation periods.²³ The qualification criteria for this group differ from the adult criteria, and families interested in pursuing this route should work with a pediatric sleep center that has experience with the device.

Where the Criteria May Be Heading

The eligibility window for Inspire has already expanded since the original STAR trial, and the trend seems to be continuing. Researchers are actively studying outcomes in patients who fall outside one or more of the current criteria, including those with higher BMI, those with AHI values above 65, and even patients with some degree of concentric palatal collapse.² The evidence on higher-BMI patients is the most mature and has already influenced real-world practice, with many centers now implanting patients up to a BMI of 35 when other criteria are met.

Whether the formal FDA labeling will expand further depends on accumulating registry data and potential new trials. For now, if you are borderline on any criterion, the most productive step is a consultation with a surgeon who implants Inspire regularly. They will have the most current sense of what their institution and your insurance plan will approve, and they can tell you whether your specific situation falls into a gray zone where the data supports trying.

1
PubMed. Hypoglossal Nerve Stimulator Outcomes for Patients Outside the U.S. FDA Recommendations
2
PubMed Central. Hypoglossal nerve stimulation in patients outside the STAR trial criteria: a systematic review
3
PubMed Central. Quality of Life Impact of Hypoglossal Nerve Stimulation with Inspire® Device in Patients with Obstructive Sleep Apnea Intolerant to Continuous Positive Airway Pressure Therapy
4
PubMed Central. Long-term trends in body mass index throughout upper airway stimulation treatment: does body mass index matter?
5
PubMed. Drug-induced sleep endoscopy in sleep-disordered breathing: report on 1,249 cases
6
PubMed. Impact of Body Mass Index and Discomfort on Upper Airway Stimulation: ADHERE Registry 2020 Update
7
PubMed. Upper Airway Stimulation in Patients With Obstructive Sleep Apnea and an Elevated Body Mass Index: A Multi-institutional Review
8
PubMed. Supine Pharyngeal Width Is Associated With Complete Concentric Palatal Collapse During Drug-Induced Sleep Endoscopy and Hypoglossal Nerve Stimulator Outcomes
9
PubMed Central. Evaluation of Drug-Induced Sleep Endoscopy as a Patient Selection Tool for Implanted Upper Airway Stimulation for Obstructive Sleep Apnea
10
Auris Nasus Larynx. Hypoglossal nerve stimulation with Inspire: An operative technique
11
PubMed Central. Insights since FDA Approval of Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea
12
Respiratory Medicine. Hypoglossal nerve stimulation for obstructive sleep apnea in adults: An updated systematic review and meta-analysis
13
PubMed. Hypoglossal nerve stimulation long-term clinical outcomes: a systematic review and meta-analysis
14
PubMed. Upper Airway Stimulation for Obstructive Sleep Apnea: Patient-Reported Outcomes after 48 Months of Follow-up
15
PubMed. Outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter German post-market study
16
PubMed. Long-Term Generator Replacement Experience in Hypoglossal Nerve Stimulator Therapy Recipients With CPAP-Intolerant Obstructive Sleep Apnea
17
Sleep Review. FDA Approves Expanded MRI Compatibility for Inspire IV and V
18
PubMed Central. Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial
19
PubMed Central. Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
20
PubMed Central. Non-CPAP Therapies for Obstructive Sleep Apnea in Adults
21
JAMA Otolaryngology–Head & Neck Surgery. Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea
22
JAMA Otolaryngology–Head & Neck Surgery. Hypoglossal Nerve Stimulation in Adolescents With Down Syndrome and Obstructive Sleep Apnea
23
International Journal of Pediatric Otorhinolaryngology. Long-term stability of hypoglossal nerve stimulation for the treatment of obstructive sleep apnea in children with Down syndrome